Should you buy today's big dip on CSL shares amid the $750 million share buyback?

A leading expert offers his verdict on CSL shares.

Key points
  • CSL shares plummeted 14.9% after the company cut its FY 2026 revenue and profit growth forecasts.
  • The market reacted negatively to CSL's strategic demerger of the Seqirus influenza vaccines business and reduced guidance, although a share buyback could provide support.
  • CSL's $750 million on-market share buyback could provide much-needed support in the months ahead.

CSL Ltd (ASX: CSL) shares are having a day to forget today.

Shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock closed yesterday trading for $211.42. In late afternoon trade on Tuesday, shares are changing hands for $179.99, down 14.9%.

Today's sharp fall in CSL shares comes following a market update this morning, which saw the company downgrade its full-year FY 2026 revenue and profit growth guidance. Today's selling continues the difficult run for stockholders that began when the company released its FY 2025 results on 19 August.

Indeed, shares in the ASX 200 biotech stock are now down 33.7% since market close on 18 August.

So, is now a good time to buy the big dip, or is it best to let the dust settle first?

A man in a business suit scratches his head looking at a graph that started high then dips, then starts to go up again like a rollercoaster.

Image source: Getty Images

CSL shares: Buy, sell, or hold?

MPC Markets' Jonathan Tacadena ran his slide rule over the company last Friday, before the release of today's market update (courtesy of The Bull).

"Shares in this global biotechnology giant were slashed after the company posted full year results on August 19," said Tacadena, who placed a hold recommendation on CSL shares prior to today's sharp sell-down and downgraded full-year guidance.

Tacadena noted:

The company generated revenue and profit growth, but investors reacted negatively to a company restructure that includes a planned demerger of the Seqirus influenza vaccines business amid the United States announcing steep tariffs on imported pharmaceuticals.

He added, "The shares fell from $271.32 on August 18 to close at $194.23 on September 26. The shares have partially recovered to trade at $218.14 on October 23."

But CSL shares could find support amid the company's ongoing share buyback.

Tacadena concluded, "We suggest investors continue holding as we expect it to test a new resistance level of $240. The company is undertaking a $750 million on-market share buyback in fiscal year 2026."

If the ASX 200 stock does recover to test resistance of $240 per share, that would represent a 33.3% upside from current levels.

What did the ASX 200 biotech company report today?

As mentioned up top, investors are bidding down CSL shares amid material guidance downgrades.

When the company released its results on 19 August, management forecast FY 2026 revenue growth in the range of 4% to 5% (in constant currency). And net profit after tax before amortisation (NPATA) excluding non-recurring restructuring costs was forecast to grow 7% to 10%.

But this morning, the company downgraded FY 2026 revenue growth guidance to 2% to 3%. Full-year NPATA growth guidance was reduced to 4% to 7%.

Investors also learned that the company's planned demerger of its Seqirus business into a separate ASX-listed entity will be pushed back "given the heightened volatility in the current US influenza vaccine market".

But the $750 million on-market buyback of CSL shares remains on track.

"We have begun a multi-year capital management program, starting with a share buyback this financial year, a clear signal of our strong cash flow and balance sheet," CSL chair Brian McNamee said today.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »